stockrowGinkgo Bioworks Holdings, Inc. (DNA) vs Rigel Pharmaceuticals, Inc. (RIGL)
- Ginkgo Bioworks Holdings, Inc. DNA 9.98 −2.63%
- Rigel Pharmaceuticals, Inc. RIGL 44.95 +0.97%
Ginkgo Bioworks Holdings, Inc. and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Rigel Pharmaceuticals, Inc. is the larger, with a market value of $838.3M against $679.1M — 1.2× the size. Ginkgo Bioworks Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Rigel Pharmaceuticals, Inc. trades at 2.6×. Rigel Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 2.18% against −23.6%. Rigel Pharmaceuticals, Inc. has the higher net margin (106.6% vs −192.0%) and the higher return on invested capital (13.7% vs −155.8%). Across the 17 metrics below, Rigel Pharmaceuticals, Inc. leads on 15 and Ginkgo Bioworks Holdings, Inc. on 2.
Valuation
Profitability
| Metric | DNA | RIGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 69.79% | 89.64% | 68.81% |
| Operating margin | (204.50%) | 26.28% | 0.00% |
| Net margin | (191.99%) | 106.59% | 0.00% |
| Free cash flow margin | (132.29%) | 6.72% | 0.00% |
| Return on equity | (52.71%) | 109.18% | (50.30%) |
| Return on assets | (23.53%) | 80.16% | (45.47%) |
| Return on invested capital | (155.79%) | 13.69% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack